Holiday Sale | Save 50%
SubscribeLogin
Holiday Sale | Save 50%
Published

First Patient Dosed in Trial of KINE-101 for CIDP

Summary by Rare Disease Advisor
The first patient in a new phase 1b/2a clinical trial to investigate KINE-101 for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) has been dosed, according to a press release from the treatment’s developer, Kine Sciences. The new trial is a dose escalation trial and will investigate increasing doses of KINE-101 in Korean patients with CIDP who have already received at least 1 frontline therapy. Read more about CIDP expe…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

South KoreaSouth Korea
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal